formulated Sor within CXCR4‐targeted lipid‐coated poly(lactic‐co‐glycolic acid) (PLGA) NMs, modifying the NMs with the CXCR4 antagonist AMD3100 to enhance systemic Sor delivery to LC and improve tumor sensitivity to treatment. The gene discussed is CXCR4; the disease is neoplasm.